News Releases

Protox Therapeutics to present at Invest Northwest Conference

Thursday, March 16, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V:  PRX) announced today that Dr. Fahar Merchant, Protox’s Chief Executive Officer, will present at the Invest Northwest 2006 CEO and Investor Forum to be held March 21 and 22, 2006 at the Bell Harbor International Conference Center in Seattle, Washington.

Now in its fifth year, Invest Northwest is a leading investment forum for senior executives from Northwest public and private life science companies to present their company’s technology and progress to institutional investors, analysts, investment bankers, fund managers, venture capitalists, angel investors and prospective corporate partners.

Dr. Merchant’s presentation will take place on March 21, 2006 at 4:35p.m. PST in the Harbor Dining Room. The presentation will also be broadcast live via an online webcast available at www.protoxtherapeutics.com. For more information about the conference, visit the conference website at www.washbio.org.

About Protox Therapeutics
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the company’s PORxin™ technology platform, therapeutic candidates are generated by engineering the naturally occurring toxin, pro-aerolysin. proaerolysin, a naturally-occurring pore-forming protoxin. These drugs become potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated, the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox has received clearance from the FDA to commence Phase 1 clinical trials with the lead compound, PRX302, for the treatment of localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia.

Link to the webcast replay of the Invest Northwest presentation Tuesday, March 21, 2006 at 4:35PM PST

For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Tel: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com